Indivior Pharmaceuticals, Inc. INDV Other accrued liabilities

Other accrued liabilities at other companies

JAN

Janus Living JAN

——

Other financials

Income statement

See full

Revenue$317.0M+19.2%

Gross profit$277.0M+24.8%

Operating income$137.0M+108%

Net income$89.0M+89.4%

EPS (diluted)$0.69+81.6%

Balance sheet

See full

Cash & equivalents$175.0M-53.0%

Total debt$509.0M+37.6%

Total equity-$144.0M+49.5%

Total assets$1.2B-12.9%

Cash flow

See full

Operating cash flow-$9.0M-112%

CapEx$20.0M+300%

Free cash flow-$29.0M-141%

Valuation

See full

Market cap$4.53B+213%

Enterprise value$4.86B+242%

P/E18×—

P/S3.5×+2.3×

Profitability

See full

Gross margin81.3%+1.5pp

Operating margin25.8%+23.3pp

Net margin19.4%+18.9pp

FCF margin-14.9%—

Returns & leverage

See full

Return on equity-117%—

Debt / equity-3.5×—

Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's other accrued liabilities?: Indivior Pharmaceuticals, Inc. (INDV) reported other accrued liabilities of $4M in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's other accrued liabilities changed year-over-year?: Indivior Pharmaceuticals, Inc. 's other accrued liabilities decreased by 94.2% year-over-year, from $69M to $4M.